

Barcelona, November 30th 2015

SIGNIFICANT EVENT

Almirall reaches an agreement to acquire 100% of Poli Group

Almirall, S.A. (ALM.MC), as per section 228 of the Royal Legislative Decree 4/2015, of 23 October 2015, approving the Restated Text of the Securities Market Act, hereby announces that:

It has signed an agreement to acquire one hundred per cent of the share capital of Poli Group Holding S.r.l., the holding company of Poli Group. Poli Group comprises three operating companies (Taurus Pharma GbmH, Polichem S.A. and Polichem S.r.l.).

The acquisition is for an Enterprise Value of €365 million plus additional potential €35 million of earn-outs conditioned to the development of the Poli Group business.

Poli Group's products are commercialized in 70 countries, with a focus on Europe and Asia. For the last 12 months ending in June 2015, Poli Group generated net sales close to ~€85 million. Poli Group has a diversified portfolio of proprietary and well-established drugs, focused on Dermatology and complemented with a strong portfolio of gynecology and respiratory products, the latter promoted through distributors.

With this acquisition Almirall will obtain a dermatology focused R&D structure with a proprietary formulation technology (HPCH) and three clinical stage Dermatology products.

With this strategic transaction Almirall continues to execute its plan to become a top global Dermatology player.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
inversores@almirall.com

